NCI-H1703 In Vitro Restriction Landmark Genome Scanning (RLGS) Assay

This assay is to provide NCI-H1703-based In Vitro Restriction Landmark Genome Scanning (RLGS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

NCI-H1703

Human

NCI-H1703 was derived from a stage 1 lung squamous cell carcinoma of a 54-year-old Caucasian male smoker.

H1703

Non Small Cell Lung Cancer

Oncology

In Vitro Restriction Landmark Genome Scanning (RLGS) Assay

Restriction landmark genome scanning is a technique used to detect genome copy number differences, mutations and gene polymorphisms. In this technique, genome is first digested with a series of restriction enzymes and the resulting fragments are labeled using radioactive isotopes. After labeling, DNA is again digested with another set of restriction enzymes and allowed to separate electrophoretically. Finally, labeled DNA fragments are then detected using autoradiography.

Genome Alteration Assays

Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.